Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty

Abstract The oral Factor Xa inhibitor rivaroxaban (Xarelto) has been the pharmacologic agent used for venous thromboembolism (VTE) prophylaxis after primary hip and knee arthroplasty (THA/TKA) at our institution since February 2012. The purpose of our study was to compare rates of VTE and major blee...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of arthroplasty 2015-07, Vol.30 (7), p.1277-1280
Hauptverfasser:	Charters, Michael A., MD, MS, Frisch, Nicholas B., MD, MBA, Wessell, Nolan M., MD, Dobson, Christopher, BS, Les, Clifford M., DVM, PhD, Silverton, Craig D., DO
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anticoagulants - therapeutic use Arthroplasty, Replacement, Hip Arthroplasty, Replacement, Knee DVT enoxaparin Enoxaparin - therapeutic use factor Xa inhibitor Factor Xa Inhibitors - chemistry Female Fibrinolytic Agents - therapeutic use Hemorrhage - prevention & control Humans Male Middle Aged Orthopedics Retrospective Studies rivaroxaban Rivaroxaban - therapeutic use Venous Thromboembolism - prevention & control VTE
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!